939775-62-9

Basic information

• Product Name: 3-(tert-butyl-diMethyl-silanyloxyMethyl)-cyclobutanone
• Synonyms: 3-(tert-butyl-diMethyl-silanyloxyMethyl)-cyclobutanone
• CAS NO: 939775-62-9
• Molecular Formula: C₁₁H₂₂O₂Si
• Molecular Weight: 214.377
• EINECS: -0
• Mol File: 939775-62-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(tert-butyl-diMethyl-silanyloxyMethyl)-cyclobutanone(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(tert-butyl-diMethyl-silanyloxyMethyl)-cyclobutanone(939775-62-9)
• EPA Substance Registry System: 3-(tert-butyl-diMethyl-silanyloxyMethyl)-cyclobutanone(939775-62-9)

Safety Data

• Hazardous Substances Data: 939775-62-9(Hazardous Substances Data)

Upstream product

• 85807-85-8 Allyloxy-tert-butyl-dimethyl-silane 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 1394119-83-5 (3-((tert-butyldimethylsilyl)oxy)cyclobutyl)methanol 
• 1245647-19-1 3-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutan-1-ol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 183616-18-4 3-(hydroxymethyl)-cyclobutan-1-one 
• 695-95-4 methyl 3-oxocyclobutanecarboxylate 
• 545882-60-8 (5,8-dioxaspiro[3.4]octan-2-yl)methanol 

Downstream Products

• 936483-27-1 C₁₅H₂₆N₂O₂Si 

Relevant articles and documents

Development of a stereoselective and scalable process for the preparation of a methylcyclobutanol-pyridyl ether

The evolution of a scalable process for the preparation of methylcyclobutanol-pyridyl ether 1 is described. Key aspects of this development including careful control of the stereochemistry, elimination of chromatography, and application to kilogram-scale

6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR

The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.